Yunnan Baiyao Group Co., Ltd (SHE: 000538), a traditional Chinese medicine (TCM) company based in Kunming, has received approval from the National Medical Products Administration (NMPA) in China to conduct a clinical study for its Category 1 chemical drug, INR101. The study will initially assess the drug in healthy volunteers and patients suffering from prostate cancer.
INR101 is an in-house developed radioactive diagnostic drug designed for PET imaging of PSMA positive lesions in prostate cancer patients. The active molecular structure of INR101 comprises a targeted ligand and the radioactive isotope fluorine [18F]. The targeted ligand can specifically bind to PSMA positive cancer cells, while the fluorine [18F] it carries emits positrons that are detected by PET imaging during decay. These positrons are annihilated, generating γ rays that are captured as X-ray signals by PET scanners and reconstructed into quantifiable three-dimensional images for the diagnosis of PSMA positive lesions.- Flcube.com
